Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 3/20 | 0.35 |
| ▸ | HPGD | P15428 | 3/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.34 |
| ▸ | TNF | P01375 | 3/20 | 0.34 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.34 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.34 |
| ▸ | EGFR | P00533 | 1/20 | 0.33 |
| ▸ | CNR1 | P21554 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21801364 | 0.85 | DAPK1 (0.39) | L3MBTL1MAPTLMNAKDM4ETP53 | |
| SCHEMBL21179013 | 0.79 | ATM (0.40) | MAPTLMNAKDM4EPOLBHSD17B10 | |
| SCHEMBL21178852 | 0.76 | SELE (0.33) | EGFRALDH1A1 | |
| SCHEMBL21801405 | 0.76 | L3MBTL1 (0.35) | L3MBTL1MAPTHPGDLMNAKAT2B | |
| SCHEMBL29456324 | 0.74 | PDE4B (0.42) | MAPTALDH1A1 | |
| SCHEMBL23885609 | 0.71 | RAB9A (0.45) | L3MBTL1MAPTHPGDKDM4EHSD17B10 | |
| SCHEMBL3401964 | 0.69 | TNF (0.45) | MAPTHPGDLMNAKAT2BTNF | |
| SCHEMBL12590776 | 0.68 | CYP1A2 (0.44) | L3MBTL1KAT2BTNFCYP4F2CYP4A11 | |
| SCHEMBL28674155 | 0.67 | JAK2 (0.44) | MAPTLMNAKDM4EPOLBMAPK1 | |
| SCHEMBL12844463 | 0.66 | L3MBTL1 (0.45) | L3MBTL1MAPTHPGDLMNACYP4F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11964988-B2 | Fused heterocyclic compounds as RET kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2024-04-23 | — | — | US | disclosed |
| EP-3849986-B1 | FUSED HETEROCYCLIC COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2022-06-08 | — | — | EP | disclosed |
| US-20220112214-A1 | FUSED HETEROCYCLIC COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2022-04-14 | — | — | US | disclosed |
| EP-3849986-A1 | FUSED HETEROCYCLIC COMPOUNDS AS RET KINASE INHIBITORS | Array Biopharma, Inc. (US) | 2021-07-21 | — | — | EP | disclosed |
| WO-2020055672-A1 | FUSED HETEROCYCLIC COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2020-03-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220112214-A1 | FUSED HETEROCYCLIC COMPOUNDS AS RET KINASE INHIBITORS | RET, ROR1, FRK | L3MBTL1 1737/4885MAPT 318/4885HPGD 3693/4885 |
| US-11964988-B2 | Fused heterocyclic compounds as RET kinase inhibitors | RET, ROR1, FRK | L3MBTL1 1737/4885MAPT 318/4885HPGD 3693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.